Puerarin attenuates cisplatin-induced rat nephrotoxicity: The involvement of TLR4/NF-κB signaling pathway
Authors:
Open Access
- 9 February 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (2) , e0171612
Abstract
Puerarin was a major isoflavonoid derived from the Chinese medical herb radix puerariae (Gegen). In present study effect of puerarin on cisplatin nephrotoxicity was evaluated. Rat model of nephrotoxicity was established by a single intraperitoneal injection of cisplatin (7mg/kg). Puerarin was administrated through caudal vein injection once per day at the dose of 10mg/kg, 30mg/kg and 50mg/kg. Biochemical assays showed that after cisplatin treatment the serum urea and creatinine increased significantly compared with control (P<0.05). Cisplatin treatment significantly increased xanthine oxidase (XO) activity and malondialdehyde (MDA) formation, and significantly decreased the levels and /or activities of enzymatic and non-enzymatic antioxidants (GSH, GPx, GST, GR, SOD, CAT), in the kidney tissues. Renal levels of TNF-α and IL-6, two important inflammatory cytokines, were also upregulated by cisplatin. Histopathological examination indicated that cisplatin treatment resulted in severe necrosis and degeneration, hyaline casts in the tubules, intertubular hemorrhage, congestion and swelling in glomerulus and leukocytes infiltration in the kidney tissues. Western blot results demonstrated that cisplatin increased TLR4 and NF-κB protein expression in the kidney tissues. However, all these changes induced by cisplatin were significantly attenuated by puerarin treatment in dose-dependent manner, which indicated the renal protective effect of puerarin. Cell culture experiments illustrated that puerarin alone treatment concentration-dependently inhibited COLO205 and HeLa tumor cell growth and dose-dependently promoted the antitumor activity of cisplatin in COLO205 and HeLa tumor cells. The promotion effects might be attributed to suppression of cisplatin-increased NF-κB p65 expression by puerarin. Taken together, findings in this study suggested that puerarin exhibited renal protection against cisplatin nephrotoxicity via inhibiting TLR4/NF-κB signaling, with no inhibition but promotion effect on the antitumor activity of cisplatin. Puerarin might be a promising adjuvant agent for cisplatin chemotherapy.Keywords
This publication has 56 references indexed in Scilit:
- Targeting the NF-κB Pathway in Cancer TherapySurgical Oncology Clinics of North America, 2013
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapyFrontiers in Oncology, 2013
- The Relationship of Thioredoxin-1 and Cisplatin Resistance: Its Impact on ROS and Oxidative Metabolism in Lung Cancer CellsMolecular Cancer Therapeutics, 2012
- Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathwayToxicology and Applied Pharmacology, 2012
- Toll-like receptor 4 activates NF-κB and MAP kinase pathways to regulate expression of proinflammatory COX-2 in renal medullary collecting duct cellsAmerican Journal of Physiology-Renal Physiology, 2012
- Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathyFree Radical Biology and Medicine, 2012
- Carnosic acid attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicityFood and Chemical Toxicology, 2011
- An integrative view of the pathophysiological events leading to cisplatin nephrotoxicityCritical Reviews in Toxicology, 2011
- TLR4 Signaling Mediates Inflammation and Tissue Injury in NephrotoxicityJournal of the American Society of Nephrology, 2008
- How dying cells alert the immune system to dangerNature Reviews Immunology, 2008